| Author (Corporate) | European Medicines Agency |
|---|---|
| Series Title | Press Release |
| Series Details | EMA/696434/2012 (26.10.12) |
| Publication Date | 26/10/2012 |
| Content Type | News |
|
A number of EU Member States, in October 2012, halted the use, as a precautionary measure, of some anti-influenza vaccines manufactured by Novartis Vaccines, based in Italy, because of a suspected quality defect. The Italian Medicines Agency (AIFA) was first informed of the suspected quality defect by the manufacturer (Novartis Vaccines). The Italian authorities took prompt precautionary action and AIFA alerted all other Member States, the European Commission and the European Medicines Agency using the established mechanisms. |
|
| Source Link | http://www.emea.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/10/news_detail_001643.jsp&mid=WC0b01ac058004d5c1 |
| Related Links |
|
| Subject Categories | Health |
| Countries / Regions | Europe, Italy |
